Next Article in Journal / Special Issue
Advances in Mammalian Cell Line Development Technologies for Recombinant Protein Production
Previous Article in Journal
An Allosteric Modulator of the Adenosine A1 Receptor Improves Cardiac Function Following Ischaemia in Murine Isolated Hearts
Previous Article in Special Issue
Characterization of N-Linked Glycosylation in a Monoclonal Antibody Produced in NS0 Cells Using Capillary Electrophoresis with Laser-Induced Fluorescence Detection
Open AccessReview

Biologics in Dermatology

London School of Hygiene and Tropical Medicine, Keppel Street, WC1E 7HT, London, UK
Whipps Cross University Hospital and the Royal London Hospital, Whitechapel, E1 1BB, London, UK
Author to whom correspondence should be addressed.
Pharmaceuticals 2013, 6(4), 557-578;
Received: 31 January 2013 / Revised: 26 February 2013 / Accepted: 7 April 2013 / Published: 17 April 2013
(This article belongs to the Special Issue Biologics)
Skin and subcutaneous diseases affect millions of people worldwide, causing significant morbidity. Biologics are becoming increasingly useful for the treatment of many skin diseases, particularly as alternatives for patients who have failed to tolerate or respond to conventional systemic therapies. Biological therapies provide a targeted approach to treatment through interaction with specific components of the underlying immune and inflammatory disease processes. This review article examines the increasing evidence base for biologics in dermatology, including well-established treatments and novel agents. View Full-Text
Keywords: biologics; biological response modifiers; immunopathogenesis; dermatology; skin disease biologics; biological response modifiers; immunopathogenesis; dermatology; skin disease
MDPI and ACS Style

Chandler, D.; Bewley, A. Biologics in Dermatology. Pharmaceuticals 2013, 6, 557-578.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop